BRISTO

## FISCAL YEAR 2017 ANNUAL REPORT

Y

MASSACHUSETTS LIFE SCIENCES CENTER

JOHN J. SBREGA HEALTH & SCIENCE BUILDING

## TABLE OF CONTENTS

#### The Bottom Line

Tax Incentive Fund and Business Developme	nt
2017 Tax Incentive Program	
Notable FY 17 Arrivals & Expansions	

Capital Fund Update & Workforce Development The Internship Challenge Investing in Infrastructure

2017 STEM Equipment & Supply Grant Awardees

nvestment Fund Update & The Way Forward	
Funding the Companies of Tomorrow	
Staying Connected	
Financial Summary	
The Way Forward	
Appendices	

## "IF YOU WANT IT TO HAPPEN, YOU NEED TO BE HERE"

This is our ethos as we move into the next generation of the Massachusetts Life Sciences Center with the support of academic institutions, companies, associations, municipalities, and the administration. With this as one of our guiding principles, we continue to work towards maintaining the Commonwealth's position as a beacon for the advancement of human health.

This ecosystem is supported by a foundation unlike any other industry. The infrastructure (lab space, equipment, supplies, etc.) required for the advancement we have seen in the life sciences cannot be compared with what's needed for the advancement you might find in construction or finance. It is crucial that our investments continue to support this innovation infrastructure, as it is some of the hardest money to come by for researchers and manufacturers. In that same vein, the workforce in Massachusetts, while being the most educated in the nation, requires an incubation period longer than any other field. We invest in students, educators, and employers to continue producing the most advanced life sciences workforce in the nation.

To that end, this year has been very exciting for the Center and for the State. We ran a full slate of programs aimed at supporting the innovation infrastructure, talent development, and sustaining the entrepreneurial growth that takes place in this ecosystem. Through these programs, we've invested more than \$77 million last fiscal year. In addition, we have received Accelerator Loan repayments from four companies, our highest repayment total in a fiscal year yet.

Going forward in the future, as you may have heard, Governor Baker has led the charge filing a bill recommending support of \$500M over five years for the MLSC. Continued support from the State Legislature, as well as our partners in academia and industry has been integral in demonstrating that no one entity is responsible for the healthy state of this industry. I speak for everyone at the Center when I say we are looking forward to continuing to play our part in the important scientific and economic work being done in Massachusetts.

Travis McCready President & CEO, Massachusetts Life Sciences Center



## IOL COMMUNITY CO



## THE BOTTOM LINE

As of June 30, 2017, the MLSC managed a portfolio of more than 630 grants and loans. Since its creation, the agency has invested or committed more than \$655 million, which has generated more than \$2.8 billion in additional investment in the Commonwealth. This has created a portfolio of more than \$3.4 billion in public-private investments in the state's life sciences ecosystem.

Project/Award	Count	\$ Amount
Capital Projects	80	\$429,758,376
Company Grants and Loans	82	\$34,655,508
Academic Research	52	\$27,256,555
Tax Incentives	126	\$116,673,777
Internships	3100+	\$18,358,822
Equipment and Supplies	191	\$17,472,246
Other Grants	106	\$11,810,065
Total:	3737	\$655,985,349

## FY17 INVESTMENT HIGHLIGHTS

• Tax incentive awards totaling more than **\$19 million** to 22 companies that committed to create more than **1,250 new jobs** by the end of the 2017 calendar year. More than 60% of awardees are located outside of Boston and Cambridge

• More than **500 interns placed** this fiscal year, more than any prior year. This year also saw the placement of the **3,000th internship** since the program's inception

### • \$39 million in Capital and STEM Equipment Grant funding to educational and research institutions across the state

• More than **\$1.5 million** awarded to support early-stage company development through the Massachusetts Ramp Up Program

• Four previous Accelerator Loan recipients repaid their loans including interest

IO 2017 BIO 2017 BIO 2017 BIO 2017 BIO 2017 BIO 2017 17 BIO 2017 B

### GOVERNOR BAKER'S \$500M COMMITMENT

Governor Charlie Baker joined the MLSC and MassBio at the BIO International Convention in San Diego to reaffirm his administration's commitment to the life sciences in the Commonwealth as well as help build the excitement of BIO taking place in Boston in 2018. Prior to arriving in San Diego, the Governor announced a proposal to continue funding the Life Sciences Initiative for five years and \$500 million. The proposal includes up to \$295 million in capital authorization and up to \$150 million job-creating tax incentives. The funding will continue to be managed by the MLSC.

BIO 2017 B

BIO

OUGH PARTI

## TAX INCENTIVE FUND & BUSINESS DEVELOPMENT

ats

## 2017 TAX INCENTIVE PROGRAM

The Life Sciences Initiative authorizes up to \$25 million in tax incentives each year for companies engaged in life sciences research and development, commercialization, and manufacturing.

A total of 39 companies applied for tax incentives over the past year, and the MLSC awarded over \$19 million to 22 companies (see below). The companies receiving tax incentive awards committed to the creation of 1,276 new jobs in the Commonwealth.

<b>Company</b> Location	Amount Awarded Jobs	Company Location	Amount Awarded Jobs
Abiomed Inc.	<b>\$750,000</b>	Acorda Therapeutics, Inc.	<b>\$495,000</b>
Danvers	50	Waltham	33
Alkermes, Inc.	<b>\$1,500,000</b>	Alnylam Pharmaceuticals, Inc.	<b>\$1,875,000</b>
Waltham	100	Cambridge	125
Anika Therapeutics, Inc. Bedford	<b>\$225,000</b> 15	Astellas Institute for Regenerative Medicine Marlborough	<b>\$750,000</b> 50
Berkshire Sterile Manufacturing, Inc. Lee	<b>\$370,000</b> 25	<b>Blueprint Medicines Corporation</b> Cambridge	<b>\$525,000</b> 35
Commonwealth Diagnostics International, Inc. Salem	<b>\$330,000</b> 22	Confer Health, Inc. Charlestown	<b>\$150,000</b> 10
EMD Holding Corporation	<b>\$1,200,000</b>	Fulcrum Therapeutics, Inc.	<b>\$270,000</b>
Billerica	80	Cambridge	18
Ginkgo Bioworks, Inc.	<b>\$300,000</b>	Insulet Corporation	<b>\$1,650,000</b>
Boston	20	Billerica	110
Kala Pharmaceuticals, Inc. Waltham	<b>\$150,000</b> 10	ProTom International Holding Corporation Wakefield	<b>\$150,000</b> 10
RADIUS HEALTH INC	<b>\$150,000</b>	Sage Therapeutics Inc.	<b>\$1,500,000</b>
Waltham	10	Cambridge	100
Shire Human Genetic Therapies, Inc. Lexington	<b>\$3,000,000</b> 200	Siemens Healthcare Diagnostics Inc. East Walpole	<b>\$2,058,000</b> 84
<b>TESARO, Inc.</b>	<b>\$1,800,000</b>	WAVE Life Sciences USA, Inc.	<b>\$735,000</b>
Waltham	120	Cambridge	49

ANIKA

In May, the MLSC celebrated with Tax Incentive awardee Anika Therapeutics for its 25th anniversary. The celebration also served as a ribbon cutting for the new 134,000 sq.ft. consolidated global manufacturing facility at the company's headquarters in Bedford. The facility will house a portion of the new 15 employees committed through its Tax Incentive award.

## SUMMARY OF TAX INCENTIVE PROGRAM FROM INCEPTION TO JUNE 30, 2017

To date, 207 awards have been authorized under this program representing \$181 million of incentives in creating over 8,800 net new jobs across the Commonwealth and maintaining them over a 5 year period.

As part of the MLSC's agreements with awardees, recipients of tax incentives are required to report job creation results to the Center by the end of the calendar year. Under the Life Sciences Act, the Department of Revenue has the authority to recover or "claw back" incentives from companies that the MLSC determines will not meet the minimum job creation threshold in their tax incentive agreement.

### AS OF JUNE 30, 2017

- There are 85 active awards from the 2012 through 2016 program years, with a combined commitment of 4,209 net new jobs under the program.
  - The awardees from the 2012 program will complete their 5 year term on December 31, 2017. The results of these awards will be reported to the MLSC in January 2018.
- Collectively, awardees from the 2009, 2010 and 2011 programs completed their 5 year term on December 31, 2014, 2015 and 2016 respectively.
- The completed awards have created, hired and maintained 1,507 net new jobs over a period of 5 years under the program.

17 awardees have declined their awards due to changes in their business or general economic conditions. 64 awardees voluntarily terminated their agreements, either by foregoing taking the tax benefits, or by returning the benefits to the Commonwealth if they had already received them. Since inception, the MLSC has decertified two awardees for not achieving the statutory thresholds.

## NOTABLE FY17 ARRIVALS & EXPANSIONS

## **Insulet Corporation**

In 2017, Billerica-based Insulet Corporation broke ground on its new 300,000+ sq.ft. facility in Acton. The space will be home to the company's only manufacturing plant in the U.S. and potentially, headquarters for the 640 person company. This purchase continues the growth the insulin pump device company has seen since its founding in 2000, after moving to a 195,000 sq.ft. space in Billerica from Bedford in 2014, and posting \$367 million in revenue in 2016.



Qilu Pharmaceutical is one of the 10 largest pharmaceutical companies in China with more than \$2 billion in sales annually. The Chinese drugmaker recently arrived in Massachusetts by purchasing a two-story office building in Brighton. A 16-person Qilu subsidiary will work on the second floor while the first floor of the 25,000 sq.ft. space is expected to be an incubator space for other local startups and entrepreneurs. Boston Mayor Marty Walsh helped celebrate the company's arrival in May.



Grunenthal, founded in 1946, is a family-owned drug development company with more than 5,000 employees worldwide and \$1.5 billion in annual revenue. In May 2017, the company announced its arrival to Massachusetts with lab space opening in the Cambridge Innovation Center. Grunenthal's CEO has expressed the possibility of consilidation of its U.S. operations (20 additional employees) to the Cambridge location in the future.



### LEO PHARMA

Her Royal Highness, Crown Princess Mary of Denmark joined life sciences leadership in Cambridge in September 2016 to open the LEO Science & Tech Hub. The Hub aims to catalyze earlystage collaborations in science and technology in order to advance the treatment of skin diseases and is the first of its kind to focus on dermatology in the Greater Boston area. Since opening, the LEO Science & Tech Hub has entered into a partnerhsip with MLSC funded Karp Lab at Brigham and Women's Hospital as well as investing in Boston based Novopyxis.

## **ThermoFisher** SCIENTIFIC

In September, the MLSC was proud to take part in the ribbon cutting officially opening Thermo Fisher Scientific's newly constructed global headquarters at 168 Third Avenue in Waltham. The 286,000 sq.ft. headquarters is home to 330 employees and was opened in conjunction with the 10th anniversary of Thermo Fisher's founding.

# Thermo Fisher's SCIENTIFIC



## HARVARD





## MERNICAL NUMBER

# CAPITAL FUND UPDATE & WORKFORCE DEVELOPMENT



## LEXINGTON MEDICAL

Lexington Medical, Inc. is a new medical device company developing patentpending abdominal surgical instruments. The company celebrated the opening of their new 8,000 square foot headquarters in Billerica in December. The new facility will house the company's current 10 employees including Harvard MBA candidate Surabhi Bhandari who began her time with Lexington Medical as an intern who participated in the MLSC's Internship Challenge program. At the conclusion of her internship with the company, Surabhi was hired as a full time employee. She is among the more than 400 interns who are hired full time by their host company at the conclusion of their internship.

## THE INTERNSHIP CHALLENGE

The Internship Challenge has continued to be the MLSC's flagship workforce development program. The year-round program is designed to expand the pool of prospective employees who have practical experience, enhance opportunities for mentoring, enable more students to explore career opportunities, and expose students to entrepreneurship.

## In FY17, the Internship Challenge Program surpassed a major milestone by funding its 3,000th internship.

To date, the program has created more than 3,150 paid internship opportunities at over 650 life sciences companies throughout the Commonwealth. Interns have represented nearly 200 different colleges and universities.

## More than 3,150

Interns Placed Since Beginning of Program

46%

84%

Women

in STEM Major

## 22% Hired Post Internship

(Part- and Full-Time)

## INVESTING IN INFRASTRUCTURE

The MLSC uses its Capital Fund to strategically invest in innovation infrastructure, design programs to train the next generation of the most educated life sciences workforce in the country, and to create and improve working spaces for early stage companies. To date, MLSC infrastructure investments have contributed or will contribute to the creation of more than 1.8 million square feet of new life sciences research and manufacturing space across the Commonwealth, while creating more than 5,200 jobs in the building trades and in the life sciences.

In FY17, more than \$39 million in capital funding was awarded to 63 research centers and life sciences training facilities (listed below and on following pages) at colleges, universities, middle schools and high schools across Massachusetts. 10 previously funded projects were completed during the year, bringing completed projects to 44 representing \$235 million in MLSC investment.

BioBuilder Learning Lab, Cambridge \$500,000

Dana-Farber Cancer Institute, Boston \$4,629,019

Framingham State University, Framingham \$454,000

Harvard Medical School, Boston \$4,345,000

Institute for Protein Innovation, Boston \$5,000,000

Mount Wachusett Community College, Gardner \$1,646,787

UMass Lowell, Lowell \$5,000,000

#### Bristol Community College, Fall River \$4,400,000

Dean College, Franklin \$297,030

Gloucester Marine Genomics Institute \$2,744,219

Harvard T. H. Chan School of Public Health, Boston \$4,912,307

Merrimack College, Andover \$500,000

Smith College, Northampton \$496,638

Westfield State University, Westfield \$75,000



## GLOUCESTER MARINE GENOMICS INSTITUTE

The Gloucester Marine Genomics Institute will establish a world-class marine genomics research institute on Gloucester Harbor, integrating the dynamic components of scientific discovery, workforce development and investment, and diversifying Gloucester's maritime economy.



The MLSC announced the more than \$39 million in Capital Infrastructure and STEM Equipment & Supply grants across the state. In February, a regional awards ceremony was held at Bristol Community College in Fall River.

## 2017 STEM EQUIPMENT & SUPPLY GRANT AWARDEES

#### Metro Boston

Boston Educational Development Foundation, Inc., Boston - \$222,415 Brooke Charter High School, Boston - \$100,000 Cambridge Rindge and Latin School, Cambridge - \$105,000 Chelsea High School, Chelsea - \$108,029 East Boston High School, Boston - \$110,000 George Keverian Middle School, Everett - \$59,629 Jeremiah E. Burke High School, Boston - \$105,700 John D. O'Bryant School of Mathematics and Science, Boston - \$186,420 Lynn English High School, Lynn - \$57,311 Madison Park Technical Vocational High School, Boston - \$110,000 Malden High School, Malden - \$26,000 Massachusetts Biotechnology Education Foundation, Cambridge - \$95,000 Medford Vocational Technical High School, Medford - \$99,516 O'Maley Innovation Middle School, Gloucester - \$56,933 Prospect Hill Academy Charter School, Cambridge - \$21,000 Snowden International School, Boston - \$101,600 TechBoston Academy High School, Boston - \$105,970

#### Southeast

Bristol-Plymouth Regional Technical High School, Taunton - \$100,000 Brockton High School, Brockton - \$109,988 Diman Regional Vocational Technical High School, Fall River - \$99,951 Global Learning Charter Public School - New Bedford \$107,982 Gloucester High School, Gloucester - \$109,154 New Bedford High School, New Bedford - \$110,000 New Bedford Middle Schools, New Bedford - \$25,000 Matthew J. Kuss Middle School, Fall River - \$40,530 Quincy Middle Schools, Quincy - \$121,890 Southeastern Regional Vocational Technical High School, North Easton -\$99,995

#### Northeast

Collins Middle School, Salem - \$39,525 Greater Lawrence Technical High School, Andover - \$93,410 Minuteman Regional Vocational Technical High School, Lexington -\$108,172 Nashoba Valley Technical High School, Westford - \$101,476 Richardson Middle School, Dracut - \$60,000 Shawsheen Valley Technical High School, Billerica - \$110,000 Tenney Grammar School, Methuen - \$49,678 Whittier Regional Vocational Technical High School, Haverhill - \$109,342

#### Western

Baystate Academy Charter Public School, Springfield - \$110,000 Chicopee Comprehensive High School, Chicopee - \$105,579 Holyoke High School and Dean Technical High School, Holyoke -\$210,798 McCann Technical School, North Adams - \$29,164 Springfield High School of Commerce, Springfield - \$110,000 Springfield Renaissance School, Springfield - \$40,040 Veritas Preparatory Charter School, Springfield - \$38,000

#### Central

Bartlett High School, Webster - \$16,112 Goodrich Academy, Fitchburg - \$105,345 Montachusett Regional Vocational Technical School, Fitchburg - \$99,697 Northbridge High School, Whitinsville - \$110,000 Quaboag Middle Innovation School, Warren - \$50,000 Sizer Charter School, Fitchburg - \$14,780 South High Community School, Worcester - \$91,609



### HIGH SCHOOL APPRENTICESHIP CHALLENGE

In May, the MLSC and the BioBuilder Educational Foundation (BioBuilder) held graduation ceremonies for the High School Apprenticeship Challenge Lab Training Program at Worcester Technical High School and LabCentral in Cambridge. Forty-three students from Greater Boston and Worcester-area public schools successfully completed an eight-week lab training program designed to prepare them for summer internships. The training was funded through a \$400,000 investment by the MLSC, which will also subsidize around 100 paid internship opportunities. The program, hosted for the second year by the MIT Department of Biological Engineering, was expanded this year to also serve students from the Worcester public schools. The Worcester-area training was hosted by Worcester Technical High School.

## INVESTMENT FUND UPDATE & THE WAY FORWARD

@ allurion

#### Pay to the Order of Massachusetts Life Sciences Center

One Million One Hundred Fifteen Thousand Eight Hundred Twenty Four and......71/100 Dollars

Through the MLSC's Accelerator Loan Program, 32 early stage life sciences companies have been awarded loans to advance a company's product commercialization. Four previous Accelerator loan Awardees repaid their loans in FY17. The companies, their loan amount from the MLSC and repayment amount are below.

**R&D ONLY** 

122811

Check No

\$1,115,824.71

Amount

1/18/17

Company	Amount Awarded	Amount Repaid	
Allurion	\$750,000	\$1,115,824.71	
Arch Therapeutics	\$1,000,000	\$1,361,268.28	
ImmuneXcite	\$984,500	\$1,332,627.83	
WolfeLabs	\$500,000	\$920,270.08	

16

## FUNDING THE COMPANIES OF TOMORROW

The MLSC announced more than \$1.6 million in awards to eight life sciences companies through the first-round of the Massachusetts Ramp-Up Program (MassRamp). MassRamp provides grant funding to promising early-stage life sciences companies. The awards are designed to help bridge the funding gaps associated with the long life sciences R&D cycle, and the high cost of translating research into commercially viable products.

Company	Location	Product Descripton	Amount Awarded
Aldatu Biosciences	Cambridge	Reagent development and testing for treatment-resistant minority variants of HIV	\$200,000
DS Labs (dba Kohana)	Canton	Complete final steps towards commercialization for breast pump platform technology via quality system development and e-commerce launch	\$200,000
HydroGlyde Coatings, LLC	Brookline	Translation of HydroGlyde Coated Condoms towards FDA approval and commercialization	\$200,000
Lariat Biosciences, Inc.	Beverly	Liquid Biopsy for Comprehensive Genetic Profiling in cancer patients	\$200,000
Micro-Leads Inc.	Boston	Clinical feasibility study to determine efficacy of stimulation electrodes to treat low-back pain	\$290,000
Platelet Biogenesis	Boston	Clinical trials regarding radiation countermeasures via bio-manufactured platelets	\$200,000
REBIScan, Inc.	Cambridge	Pediatric lazy-eye detection through retinal imaging	\$145,250
Snapdragon Chemistry	Cambridge	Development of flow chemical reactors for atomization of medicinal chemistry process	\$200,000



Cre8MDI is a Chelmsford based medical device company whose technology is designed to measure arterial stiffness, a proven predictor for cardiovascular disease. Cre8MDI was a Milestone Achievement Program (MAP) awardee in 2015. The MAP grant allowed the company to maintain their pace of development. Cre8MDI is now past the prototype stage, closing in on Phase 1 trials where performance of the system can be validated. Additionally, MLSC funding constituted a third of Cre8MDI's overall funding which reduced its dilution and increased the company's value to investors.



## **GETTING READY FOR 2018**

In anticipation of the return of the BIO International Convention to Boston in 2018, the MLSC and MassBio coordinated on a promotional strategy to help drive interest in the event while in San Diego, which included:

- A large networking event held at Petco Park attended by Governor Baker
- Coffee and donuts from Dunkin' Donuts within the pavilion
- A clear unified message supporting the convention in Massachusetts
- Promotional items with the new Massacshuetts Pavilion Logo & Tagline:



## STAYING CONNECTED

Communication and marketing efforts continued to be a key part of MLSC outreach. The MLSC continued to engage with the life sciences community through the news media, and digitally through the Weekly Digest, social media platforms, and the MLSC website. The MLSC also participated in numerous public and private events around the state and the country to explain the benefits of doing business in Massachusetts.

#### Blog of Life Sciences Discourse

MLSC President & CEO Travis McCready began his own blog providing insight and views on the life sciences in Massachusetts. Popular posts have covered wearables and human health, female leadership in the life sciences, and the challenges that face the biomanufacturing industry in the Commonwealth. Response from the community has been strong, and with continued activity, the blog will provide an non-traditional view of the industry from a respected source.

#### **MLSC Social Media Presence**

The MLSC continued being an engaging presence on social media, specifically through Twitter. In FY17, the MLSC increased Twitter followers by more than 1,500, and saw an increase in engagement with followers by more than 50%.

#### **Traditional Media**

Newspaper, television and online print remained a focus for traditional communication efforts throughout FY17. Travis continued his monthly appearances on New England Cable News, discussing the latest news in the industry. MLSC coverage in print and online media remained consistent with the Center being covered directly or mentioned in a news item more than 750 times over the course of FY17.

## ADDITIONAL MLSC FUNDING IN FY17

Throughout the fiscal year, the MLSC - at the discretion of the CEO and with the approval of the Board of Directors - can provide additional funds to new and existing programs or initiatives. In FY17 the MLSC provided six such grants, listed below.

Science from Scientists - **\$50,000** Noonan Scholars - **\$50,000** Latino STEM Alliance - **\$50,000**  Dearborn Academy/Boston Plan for Excellence - **\$50,000** Boys and Girls Club of Brockton - **\$50,000** Lever, Inc - **\$44,350** 

A **\$250,000 grant**, outside of the CEO's discretionary grants, was made to the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS) through Massachusetts General Hospital. MassCATS, located at MGH, is a collaboration between the MLSC, MGH, and industry partners, including AbbVie, Biogen, Janssen Pharmaceuticals, Inc., Merck and Sunovion Pharmaceuticals. Total funding for MassCATS totals **\$1.5** million

### FINANCIAL SUMMARY

The following summarizes the Statement of Net Position and Revenue, Expenses and Changes in Net Position for fiscal years 2017 and 2016

	June 30, 2017	June 30, 2016
Assets:		
Current assets:	\$ 80,756,645	\$ 69,219,571
Assets held on behalf of Neuroscience Consortium	\$ 1,576,089	\$ 773,873
Assets held in escrow	-	-
Noncurrent assets	\$ 3,848,268	\$ 6,483,777
Capital assets	\$ 42,162	\$ 40,234
Total assets	\$ 86,223,164	\$ 76,517,455
Liabilities:		
Current liabilities	\$ 46,091,475	\$ 30,877,582
Noncurrent liabilities	\$ 1,576,089	\$ 773,873
Total liabilities	\$ 47,667,564	\$ 31,651,455
Net Position:		
Net investment in capital assets	\$ 42,162	\$ 40,234
Unrestricted	\$ 38,513,438	\$ 44,825,766
Total net position	\$ 38,555,600	\$ 44,866,000
Total liabilities and net position	\$ 86,223,164	\$ 76,517,455
Statements of Revenues, Expenses and Changes in Net Position		
Revenues and Expenses:		
Operating revenues	\$ 52,396,514	\$ 54,764,313
Operating expenses	(59,004,062)	(65,884,705)
Operating loss	(6,607,548)	(11,120,392)
Nonoperating revenues	\$ 297,148	\$ 170,495
Capital contributions	-	\$ 10,000,000
(Decrease) increase in net position	(6,310,400)	(949,897)
Net position:		
Beginning of year	\$ 44,866,000	\$ 45,815,897
End of year	\$ 38,555,600	\$ 44,866,000

## THE WAY FORWARD


The state budget provides for an FY18 investment fund appropriation of \$10 million, contingent on the State Comptroller's declaration of a consolidated net surplus for FY17. The MLSC appreciates, and is grateful to Governor Baker and his Administration, and the entire State Legislature for prioritizing this funding within the state budget. We also thank those who have been integral in establishing the MLSC as the organization it is today and for helping us achieve the success we are known for.

It has been encouraging to find that when travelling the state or country for ribbon cuttings, speaking engagements, conferences, or meetings, that the reputation of the Massachusetts life sciences ecosystem precedes us:

- Our young students in STEM programs are getting and will continue to have access to the tools and resources neccesary to become invested and interested in the life sciences.
- A balanced ecosystem that supports pharmaceuticals, medical device, and additional verticals equally, not found anywhere else in the country.
- Public and private institutes that individually, could support its own "micro-climate," but together creates the densest and arguably, most advanced, population of institutions in the world.

The work being done here is second to none, and our job is to make sure everyone who we come in contact with understands that.

With the support of the Baker-Polito Administration, the State Legislature, our colleagues in industry and academia, and the stakeholders across the Commonwealth, the Massachusetts Life Sciences Center is setup perfectly to be a key cog supporting this industry and extolling the virtues of maintaining a presence in Massachusetts. We have shed the moniker of an "initiative" and operate strategically as an agency with the tools necessary to continue making substantial improvements to the life sciences. With all this in place, the Massachusetts Life Sciences Center is excited to help lead the Commonwealth forward as the life sciences industry continues to evolve.



#### Appendices for the Massachusetts Life Sciences Center Fiscal Year 2017 Annual Report

#### Capital Awards from Inception through June 30, 2017

Infrastructure Investments to Accelerate Innovation	Total Award	Year of Award	Status at End of FY 2017
Bay Path College	\$50,000	FY 2013	Completed
Bay Path University	\$500,000	FY 2015	Completed
BayState Medical Center/Health Informatics & Technology Innovation Center	\$5,500,000	FY 2013	Completed
Berkshire Community College	\$500,000	FY 2015	Completed
BioBuilder	\$500,000	FY 2017	Ongoing
Boston Children's Hospital	\$4,014,031	FY 2013	Completed
Boston Children's Hospital	\$2,263,133	FY 2015	Ongoing
Boston University Biomedical Lab and Clinical Sciences Program	\$180,000	FY 2015	Completed
Boston University Business Innovation Center	\$363,750	FY 2015	Completed
Boston University Medical School	\$1,743,648	FY 2015	Completed
Brigham & Women's Hospital	\$2,603,537	FY 2015	Ongoing
Bristol Community College	\$4,400,000	FY 2017	Ongoing
Bunker Hill Community College	\$200,000	FY 2013	Completed
Cape Cod Community College	\$395,485	FY 2014	Completed
City of Taunton	\$55,000	FY 2014	Completed
Dana Farber Molecular Cancer Imaging Center	\$10,000,000	FY 2012	Completed
Dana-Farber Cancer Institute	\$4,629,019	FY 2017	Ongoing
Dean College	\$297,030	FY 2017	Ongoing
Framingham State University	\$454,000	FY 2017	Ongoing
Framingham State University	\$3,000,000	FY 2014	Completed
Framingham Wastewater and Pumping Station	\$12,860,534	FY 2009	Completed
Gloucester Marine Genomics Institute	\$2,744,219	FY 2017	Ongoing
Harvard Medical School	\$4,345,000	FY 2017	Ongoing
Harvard Medical School	\$5,000,000	FY 2013	Completed
Harvard School of Public Health	\$4,912,307	FY 2017	Ongoing
Holyoke Community College	\$3,800,000	FY 2013	Completed
Holyoke Community College	\$300,000	FY 2015	Ongoing
nstitute for Protein Innovation	\$5,000,000	FY 2017	Ongoing
Joslin Translational Center for the Cure of Diabetes	\$5,000,000	FY 2012	Completed
Just-A-Start	\$46,099	FY 2014	Completed
Just-A-Start	\$49,992	FY 2015	Completed
LabCentral	\$4,955,515	FY 2013	Completed
LabCentral	\$5,000,000	FY 2014	Ongoing
MA Green High Performance Computing Center	\$4,540,000	FY 2013	Ongoing
Marine Biological Laboratory in Woods Hole	\$10,000,000	FY 2009	Completed

#### Capital Awards from Inception through June 30, 2017

Infrastructure Investments to Accelerate Innovation	Total Award	Year of Award	Status at End of FY 2017
Massachusetts Institute of Technology	\$1,838,000	FY 2015	Completed
MassBay Community College	\$50,000	FY 2014	Completed
MassBiologics-UMass Medical School	\$5,000,000	FY 2014	Completed
Merrimack College	\$500,000	FY 2017	Ongoing
Middlesex Community College	\$36,664	FY 2013	Completed
Middlesex Community College	\$3,000,000	FY 2014	Ongoing
Mount Wachusett Community College	\$500,000	FY 2014	Ongoing
Mt. Wachusett Community College	\$1,646,787	FY 2017	Ongoing
Museum of Science "Hall of Human Life"	\$5,000,000	FY 2012	Completed
New Bedford Economic Development Council	\$75,000	FY 2014	Completed
North Shore Biotech Consortium	\$5,000,000	FY 2014	Ongoing
Northern Essex Community College	\$1,242,000	FY 2013	Completed
Pittsfield Economic Development Authority	\$55,000	FY 2013	Completed
Pittsfield Economic Development Authority	\$9,670,000	FY 2014	Ongoing
Quincy College	\$78,799	FY 2013	Completed
Quincy College	\$500,000	FY 2014	Ongoing
Quinsigamond Community College	\$310,000	FY 2013	Completed
Quinsigamond Community College	\$499,880	FY 2014	Completed
Quinsigamond Community College	\$5,000,000	FY 2015	Ongoing
Regis College	\$50,000	FY 2013	Completed
Regis College	\$355,000	FY 2015	Completed
Roxbury Community College	\$3,000,000	FY 2015	Ongoing
Smith College	\$489,435	FY 2017	Ongoing
Springfield Technical Community College	\$85,673	FY 2013	Completed
Springfield Technical Community College	\$972,850	FY 2015	Completed
The Forsyth Institute	\$4,133,215	FY 2013	Completed
The Forsyth Institute	\$2,210,229	FY 2015	Ongoing
Tufts/Cummings School of Veterinary Medicine, NE Regional Biosafety Lab in Grafton	\$9,500,000	FY 2009	Completed
UMass Amherst Life Sciences Laboratories	\$95,000,000	FY 2013	Ongoing
UMass Boston /Dana Farber Center for Personalized Cancer Therapy	\$2,000,000	FY 2011	Ongoing
UMass Boston /Dana Farber Center for Personalized Cancer Therapy Expansion	\$8,000,000	FY 2014	Ongoing
UMass Boston VDC	\$588,848		Ongoing
UMass Dartmouth Advanced Technology Manufacturing Center (ATMC)	\$11,400,000		Completed
UMass Dartmouth/Vector Manufacturing Center	\$20,600,000		Completed
UMass Lowell Emerging Technologies and Innovation Center	\$10,000,000	FY 2012	Completed

#### Capital Awards from Inception through June 30, 2017

Infrastructure Investments to Accelerate Innovation	Total Award	Year of Award	Status at End of FY 2017
UMass Lowell Innovation Hub	\$1,000,000	FY 2014	Ongoing
UMass Lowell M2D2	\$4,046,697	FY 2014	Ongoing
UMass Medical School	\$5,000,000	FY 2015	Ongoing
UMass Medical School Albert Sherman Center	\$90,000,000	FY 2010	Completed
University of Massachusetts Lowell	\$5,000,000	FY 2017	Ongoing
Venture Cafe	\$347,000	FY 2014	Ongoing
Wellesley College	\$50,000	FY 2015	Ongoing
Western New England University	\$500,000	FY 2014	Completed
Westfield State University	\$75,000	FY 2017	Ongoing
Worcester Polytechnic Institute (Biomanufacturing Education & Training Center)	\$5,150,000	FY 2010	Completed

Total Number of Projects	80
Total Investments in Capital Projects	\$ 429,758,376
Total Number of Projects for Which MLSC Funding is Complete	44
Total Investment in Projects for Which MLSC Funding is Complete	\$ 235,146,135
Total Number of Ongoing Projects	36
Total Investment inOngoing Projects	\$ 194,612,241

#### List of Certified Active Life Sciences Companies as of June 30, 2016

As part of the MLSC's award process, any for-profit company that receives funds through any of the MLSC's competitive programs must be certified as a "certified life sciences company" in accordance with the MLSC's statutory authority. The companies below are currently certified by the MLSC.

3Derm Systems, Inc.	Cambridge	Cre8MDI LLC	Chelmsford
908 Devices, Inc.	Boston	CSA Medical, Inc.	Lexington
AbbVie Inc	Worcester	DePuy Othopaedics, Inc.	Raynham
Abiomed Inc	Danvers	DetectonGen Inc.	Grafton
Acorda Therapeutics, Inc.	Waltham	DS Labs (dba Kohana)	Canton
Aegerion Pharmaceuticals, Inc.	Cambridge	EMD Holding Corporation	Billerica
Agile Devices Inc.	Cambridge	EMD Millipore Corporation	Billerica
Akili Interactive Labs Inc.	Boston	Emulate, Inc.	Boston
Akita Innovations, Inc.	North Billerica	Enanta Pharmacueticals, Inc.	Watertown
Akrivis Technologies LLC	Cambridge	Energesis Pharmaceuticals Inc.	Cambridge
Alcyone Lifesciences, Inc.	Concord	Epizyme, Inc.	Cambridge
Aldatu Biosciences	Cambridge	Eutropics Pharmaceuticals, Inc.	Cambridge
Alexion Pharmaceuticals, Inc.	Lexington	Excellims Corporation	Acton
Alkermes, Inc.	Waltham	Extend Biosciences Inc.	Cambridge
Allurion Techologies, Inc.	Wellesley	Felicitex Therapeutics Inc.	Newton
Alnylam Pharmaceuticals, Inc.	Cambridge	First Light Biosciences, Inc.	Bedford
Amgen Inc.	Cambridge	Foundation Medicine, Inc.	Cambridge
Anika Therapeutics, Inc.	Bedford	Fulcrum Therapeutics, Inc.	Cambridge
Aquinnah Pharmaceuticals, Inc.	Cambridge	Ginkgo Bioworks, Inc	Boston
Arch Therapeutics, Inc.	Framingham	Guided Surgery Solutions, LLC	Wellesley
Astellas Institute for Regenerative Medicine	Marlborough	Hepatochem, Inc.	Cambridge
Barrett Technology Inc.	Newton	HydroGlyde Coatings, LLC	Brookline
Berkshire Sterile Manufacturing	Lee	Immunexcite, Inc.	Waltham
Bio2 Technologies, Inc.	Woburn	InsomniSolv, Inc.	Beverly
Biogen, Inc.	Cambridge	Instrumentation Laboratory Company	Bedford
Bluebird Bio, Inc.	Cambridge	Insulet Corporation	Billerica
Blueprint Medicines Corporation	Cambridge	inviCRO, LLC	Boston
Boston Heart Diagnostics Corporation	Framingham	Jounce Therapeutics, Inc.	Cambridge
Cam Med LLC	West Newton	Juno Therapuetics, Inc.	Waltham
Charles River Laboratories, Inc.	Wilmington	Kala Pharmaceuticals, Inc	Waltham
Charm Sciences, Inc.	Lawrence	KEW Group Inc.	Cambridge
Cognition Medical Corp.	Cambridge	Lantern Pharma, Inc.	Cambridge
Commonwealth Diagnostics International, Inc.	Salem	Lariat Biosciences, Inc.	Beverly
Confer Health	Charlestown	LayerBio, Inc.	Arlington

#### List of Certified Active Life Sciences Companies as of June 30, 2016

As part of the MLSC's award process, any for-profit company that receives funds through any of the MLSC's competitive programs must be certified as a "certified life sciences company" in accordance with the MLSC's statutory authority. The companies below are currently certified by the MLSC.

	5
LeMaitre, Inc.	Burlington
LFB USA, Inc.	Framingham
Lightlab Imaging, Inc.	Westford
Lumicell Diagnostics, Inc.	Wellesley
MedicaMetrix, Inc.	Wayland
Merrimack Pharmaceuticals, Inc.	Cambridge
Micro-Leads, Inc.	Boston
Moderna Therapeutics, Inc.	Cambridge
Momenta Pharmaceuticals, Inc.	Cambridge
Myomo, Inc.	Cambridge
New England Biolabs, Inc.	Ipswich
Nitto Denko Avecia Inc.	Milford
Nova Biomedical Corporation	Waltham
NxStage Medical, Inc.	Lawrence
Parsagen Diagnostics, Inc.	Boston
PathMaker Neurosystems, Inc.	Boston
PerkinElmer, Inc.	Waltham
Pharmalucence, Inc.	Bedford
Platelet Biogenesis, Inc.	Chestnut Hill
PNP Research Corporation	Drury
ProTom International Holding Corporation	Wakefield
Quanterix Corporation	Cambridge
Quest Diagnostics, Incorporated	Cambridge
Radius Health, Inc.	Waltham
REBIScan, Inc.	Cambridge
Revolution Biosciences LLC	Boston
Riparian Pharmaceuticals	Boston
Sage Therapeutics Inc.	Cambridge
Seres Therapeutics, Inc.	Cambridge
Shire Human Genetic Therapies, Inc.	Lexington
Siemens Healthcare Diagnostics Inc.	East Walpole
Snapdragon Chemistry	Cambridge
LX Medical Corporation	Westwood

Masy Systems, Inc.	Pepperell
Matrivax R&D Corporation	Boston
MCC Global Laboratories, Inc.	Beverly
SQZ Biotechnologies Company	Boston
Strohl Medical Technologies, Inc.	Weymouth
T2Biosystems, Inc.	Lexington
Takeda Pharmaceuticals America, Inc.	Cambridge
TESARO, Inc.	Waltham
Triton Systems, Inc.	Chelmsford
uniQure, Inc.	Lexington
Vaxess Technologies, Inc.	Cambridge
WAVE Life Sciences	Cambridge
Windgap Medical	Somerville
Wolfe Laboratories, Inc.	Woburn

#### 2016-2017 Internship Challenge Host Companies

480 Biomedical, Inc.	Watertown
A Chemtek, Inc.	Worcester
AB Biosciences, Inc.	Boston
Abpro Labs	Woburn
Access Vascular, Inc.	Woburn
Acetylon Pharmaceuticals, Inc.	Boston
Adeptrix Corp	Beverly
AdMeTech Foundation	Boston
Admetsys Corporation	Boston
Advanced Radiation Therapy, LLC	Tyngsboro
Advanced Research and Development	North Andover
AdvanDx, Inc.	Woburn
Advantagene, Inc.	Boston
Advirna, LLC	Cambridge
Agrivida	Medford
Akaza Research, LLC	Waltham
Akcea Therapeutics	Cambridge
Akili Interactive Labs, Inc.	Boston
Aldatu Biosciences	Cambridge
Allergy Amulet Inc.	Lowell
Allurion Technologies	Natick
Alzheimer Disease Center	Quincy
Amplyus	Cambridge
Anderson Biotest, LLC	Bedford
Antagen Pharmaceuticals, Inc	Boston
Antera Therapeutics	Boston
Apex Neuro, Inc.	Boston
Aphios Corporation	Woburn
Applied Photophysics, Inc.	Beverly
Aquinnah Pharmaceuticals, Inc.	Cambridge
Arietis Corporation	Boston
Arsia Therapeutics	Cambridge
Artaic, LLC	Boston
Asaman, Inc.	Marlboro
Atlantic Lab Equipment, LLC	Salem
Auxocell Laboratories, Inc.	Cambridge
Averica Discovery Services, Inc.	Marlboro
Bach Pharma, Inc.	North Andover
Beantown Biotech, LLC.	Natick
Behavioral Health Innovators, Inc.	S. Chatham
Berkshire Sterile Manufacturing, Inc.	Lee
Bio2 Technologies	Woburn
BioAxone Biosciences, Inc.	Cambridge
BioBright, LLC.	Cambridge
Biomedical Research Models, Inc.	Worcester

BioSensics LLC	Cambridge	E
Biostage, Inc.	Holliston	E
Blue Sky Biotech, Inc.	Worcester	E
Boston 3T Biotechnologies	Fall River	E
Boston Device Development Inc.	Newton	E
Boston MedTech Advisors	Dedham	E
Boston Microfluidics, Inc.	Medford	e
Boston Micromachines Corporation	Cambridge	E
Boyd Technologies	Lee	E
BrainSpec	Boston	E
Cam Med, LLC	West Newton	E
Cambridge Scientific Products	Watertown	E
Catapult Product Development, Inc.	Waltham	E
Cellanyx Diagnostics, LLC	Beverly	E
Celltreat Scientific Products	Shirley	E
Cephos Corp.	Pepperell	E
Cerulean Pharma, Inc.	Waltham	E
China Med Device	North Andover	F
Cisbio US, Inc.	Bedford	F
Clear Breath LLC	Cambridge	F
Cocoon Biotech, Inc.	Lowell	F
Common Sensing, Inc.	Cambridge	F
Compass Biomedical	Hopkinton	
Concert Medical, LLC.	Norwell	C
Confer Health	Boston	C
Constant Therapy, Inc.	Lexington	
Constellation Pharmaceuticals	Cambridge	C
CONTINUUS Pharmaceuticals, Inc.	Woburn	C
Convergent Dental	Natick	C
Corbus Pharmaceuticals, Inc.	Norwood	C
Court Square Group, Inc.	Springfield	C
Courtagen Life Sciences, Inc.	Woburn	F
Covaris, Inc.	Woburn	F
CreaGen Biosciences, Inc.	Woburn	F
Cure Forward corp.	Cambridge	H
CuriRx, Inc.	Wilmington	F
CYTO Consulting	Lexington	H
Cytrellis Biosystems, LLC	Boston	h
Delsys, Inc.	Natick	h
Dermalytica, Inc.	Northborough	
Detector Technology, Inc.	Palmer	i
Diagnosys LLC	Lowell	I
Dicerna Pharmaceuticals	Watertown	l
DNA Medicine Institute	Cambridge	j(
DoDoc Corp.	Boston	le

Embora NouroThorapoutics Inc	Sudbury
Embera NeuroTherapeutics, Inc.	,
EMBR Labs, Inc. Enable Life Sciences, LLC	Cambridge
	Cambridge
EnBiotix, Inc.	Cambridge
Endobiome	Beverly
EndoSim, LLC	Bolton
enEvolv, Inc.	Boston
Enlivity Corporation	Newton
Enumeral Biomedical	Cambridge
EpigenDx, Inc.	Hopkinton
Essential Life Solutions Ltd	Stoughton
Etiometry, LLC	Boston
Eutropics Pharmaceuticals	Cambridge
Everost, Inc.	Sturbridge
Experfy Inc.	Boston
Extend Biosciences, Inc.	Cambridge
EyeNetra, LLC	Somerville
Fairbanks Pharmaceuticals	Concord
Five Star Manufacturing, Inc.	New Bedford
FloDesign Sonics	Wilbraham
Fractyl Laboratories, Inc.	Waltham
FTL Labs Corporation	Amherst
G & F Medical, Inc.	Danvers
Gel4Med	Boston
Genocea Biosciences, Inc.	Cambridge
GenoSpace, LLC	Cambridge
Gentuity, LLC	Sudbury
Giner, Inc.	Newton
Gliese 623B	Lowell
Glycologix, LLC	Beverly
Guided Surgery Solutions, LLC	Wellesley Hills
Health Policy Associates, Inc.	Westwood
HelixBind, Inc.	Marlborough
Hemedex Inc.	Cambridge
HepatoChem, Inc.	Beverly
Hepatochem, mc. Hstar Technologies Co.	Cambridge
	Ű
Human Systems Integration	Walpole
Immunetics, Inc Innoblative Designs	Boston Mansfield
Intertech Engineering Associates	Westwood
inviCRO, LLC	Boston
Invitrometrix Corporation	Lowell
InVivo Therapeutics Corporation	Cambridge
iOmics Corporation	Cambridge
IonSense	Saugus
	200300

### 2016-2017 Internship Challenge Host Companies

iSpecimen, Inc.	Lexington
Isto Biologics (Arteriocyte Medical Systems)	Hopkinton
J&J Machine Company, Inc.	Marlborough
Jana Care	Boston
Jounce Therapeutics	Cambridge
JuvoBio Pharmaceuticals Inc.	Worcester
KnipBio	Lowell
LabMinds, Inc.	Boston
Lariat Biosciences, Inc.	Beverly
Lattice Automation, Inc.	Boston
LaunchPad Medical, LLC	Boston
LaVoie Health Sciences	Charlestown
Lexington Medical, Inc.	North Billerica
Liberating Technologies, Inc.	Holliston
Life Science Nation	Boston
Little Sparrows Technologies, LLC	Winchester
Luminopia	Cambridge
Lumme Inc.	Amherst
Manus Biosynthesis, Inc.	Cambridge
Matrivax R&D Corporation	Boston
MCR Labs, LLC	Framingham
MedicaMetrix, Inc.	Lowell
MedPanel	Cambridge
Medrobotics Corporation	Raynham
Merrimack Ventures, LLC	Cambridge
Microbiotix, Inc.	Worcester
MicroCHIPS, Inc.	Lexington
Micro-Leads, Inc.	Boston
Millimeter Wave Systems, LLC	Amherst
MX Orthopedics	Lexington
Myomo, Inc.	Cambridge
N2 Biomedical, LLC	Bedford
Nano Terra Inc.	Cambridge
nanoView Diagnostics, Inc.	Boston
NEHI, Inc.	Cambridge
NeuroMetrix, Inc.	Waltham
Neuronix, Inc.	Holliston
NeuroScouting LLC	Cambridge
New England Peptide, LLC	Gardner
Nexcelom Bioscience, LLC	Lawrence
NinePoint Medical, Inc.	Bedford
Nix, Inc.	Cambridge
Nona Research Foundation, Inc.	Cambridge
North East Biomedical, Inc.	Tyngsborough
Northeast Plastics, Inc.	Wakefield
NovoBiotic Pharmaceuticals, LLC	Cambridge
OMNI Life Science, Inc.	East Taunton

Opus KSD, Inc.	Halifax
Parsagen Diagnostics, Inc.	Boston
Phosphorex, Inc.	Hopkinton
PixarBio Corporation	Medford
Platelet Biogenesis	Boston
PLC Medical Systems, Inc.	Milford
PlenOptika,Inc.	Boston
PNA Innovations, Inc.	Woburn
Podimetrics, Inc.	Somerville
Polestar Technologies	Needham
Polycarbon Industries (PCI Synthesis, Inc.)	Newburyport
Portela Soni Medical, LLC	Attleboro
Pressure BioSciences, Inc.	South Easton
Privo Technologies	Peabody
ProterixBio, Inc.	Billerica
Protom International Holding Corporation	Wakefield
Proveris Scientific Corporation	Marlboro
Quality Systems Integration, LLC	North Reading
Quanterix Corporation	Lexington
Quantum Diamond Technologies, Inc.	Somerville
Quiet Therapeutics, Inc.	Lexington
Quintara Biosciences	Boston
Ra Pharmaceuticals	Cambridge
Raiing Medical, Inc.	Boston
RainDance Technologies, Inc.	Billerica
RAN Biotechnologies, Inc.	Beverly
Ras Labs, LLC	Quincy
Real Food Solutions, LLC	Lenox
Respiratory Motion, Inc	Waltham
ReSurfX, LLC	Lexington
ReWalk Robotics, Inc.	Marlborough
Right Submission, LLC	Newton
Riparian Pharmaceuticals, Inc.	Cambridge
Robie Device Group	North Andover
Rogers Sciences, Inc.	Boston
Rowat Management Services, LLC	Framingham
RRMAE Engineering, LLC	Boxborough
RXi Pharmaceuticals	Marlboro
S2N Health, LLC	Boston
SafePath Medical, Inc.	Amesbury
Sample6 Technologies, Inc.	Boston
Samplify Bio, Inc.	Beverly
SBH Sciences, Inc.	Natick
Securus Medical Group, Inc.	Beverly
Seeding Labs	Boston
Selecta Biosciences, Inc.	Watertown
SemiNex Corporation	Peabody

Senscio Systems, Inc.	Boxboro
Sentien Biotechnologies, Inc.	Medford
SeqLL	Woburn
seqWell, Inc.	Beverly
SevenOaks Biosystems	Cambridge
Seventh Sense Biosystems	Medford
Shaser, Inc.	Lexington
Shepherd Therapeutics, LLC	Boston
Siamab Therapeutics, Inc.	Cambridge
SofregenMedical, Inc.	Cambridge
Spring Bank Pharmaceuticals, Inc.	Milford
SQZ Biotechnologies Company	Boston
STAR Analytical Services	Bedford
STC Biologics, Inc.	Cambridge
TARIS Biomedical	Lexington
Tarveda Therapeutics	Watertown
Tetragenetics, Inc.	Arlington
TetraScience	Boston
Thermedical, Inc.	Waltham
Thrive Biosciences, Inc.	Beverly
Tissue Vision, Inc.	Somerville
Ultivue Inc.	Cambridge
Union Biometrica, Inc.	Holliston
Unum Therapeutics	Cambridge
Vaxess Technologies, Inc.	Cambridge
Vedanta Biosciences, Inc.	Cambridge
Veralase LLC	Middleton
Veritas Genetics, Inc.	Danvers
Vertical Biometrics, LLC	Newton
Viatar	Lowell
Virtudent	Boston
Vittamed Corporation	Lexington
Vivonics, Inc.	Sudbury
VocaliD, Inc.	Belmont
Warner Babcock Institute for Green Ch	Wilmington
WaveGuide Corporation	Cambridge
WorldCare Clinical, LLC	Boston
X-CHEM, Inc.	Waltham
Xios Therapeutics, Inc.	Waltham
Xtal BioStructures, Inc.	Natick
XTuit Pharmaceuticals, Inc.	Waltham
Yurogen Biosystems	Worcester
Zaiput Flow Technologies	Cambridge
ZATA Pharmaceuticals, Inc.	Worcester
ZS Genetics, Inc.	Wakefield



1000 Winter Street, Suite 2900 Waltham, MA 02451 P: 781.373.7777 www.masslifesciences.com info@masslifesciences.com